Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
The Intersection: Crypto and Wall Street This Week » 09:44
08/07/20
08/07
09:44
08/07/20
09:44
BTC

Bitcoin

$0.00 /

+ (+0.00%)

, BITCOIN

Bitcoin

$0.00 /

+ (+0.00%)

, TWTR

Twitter

$37.69 /

+ (+0.00%)

, GS

Goldman Sachs

$204.29 /

+ (+0.00%)

, AMD

AMD

$86.70 /

+ (+0.00%)

, NVDA

Nvidia

$453.42 /

+ (+0.00%)

, OSTK

Overstock.com

$94.11 /

+ (+0.00%)

, IDEX

Ideanomics

$1.65 /

+ (+0.00%)

, RIOT

Riot Blockchain

$4.22 /

+ (+0.00%)

, TEUM

Pareteum

$0.79 /

+ (+0.00%)

, SRAX

Srax

$2.85 /

+ (+0.00%)

As bitcoin, ethereum and…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$37.69 /

+ (+0.00%)

TEUM Pareteum
$0.79 /

+ (+0.00%)

RIOT Riot Blockchain
$4.22 /

+ (+0.00%)

OSTK Overstock.com
$94.11 /

+ (+0.00%)

NVDA Nvidia
$453.42 /

+ (+0.00%)

IDEX Ideanomics
$1.65 /

+ (+0.00%)

GS Goldman Sachs
$204.29 /

+ (+0.00%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

AMD AMD
$86.70 /

+ (+0.00%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

01/23/20 Morgan Stanley
PayPal acceptance gap widens against Amazon, Bitcoin, says Morgan Stanley
BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

TWTR Twitter
$37.69 /

+ (+0.00%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/24/20 Truist
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
GS Goldman Sachs
$204.29 /

+ (+0.00%)

08/06/20 Piper Sandler
Now is the time to buy Goldman Sachs, says Piper Sandler
07/20/20 Berenberg
Goldman Sachs price target raised to $200 from $160 at Berenberg
07/16/20 DA Davidson
Goldman Sachs price target raised to $238 from $215 at DA Davidson
07/16/20 Oppenheimer
Goldman Sachs price target raised to $355 from $335 at Oppenheimer
AMD AMD
$86.70 /

+ (+0.00%)

08/04/20 Jefferies
AMD price target raised to $95 from $86 at Jefferies
07/29/20
Fly Intel: Top five analyst downgrades
07/29/20
Fly Intel: Top five analyst upgrades
07/29/20 JPMorgan
AMD price target raised to $62 from $52 at JPMorgan
NVDA Nvidia
$453.42 /

+ (+0.00%)

08/03/20 Morgan Stanley
Synergies unclear if Nvidia buys controlling ARM interest, says Morgan Stanley
07/24/20 Raymond James
Intel 7nm delay positive for AMD, TSMC, Nvidia, says Raymond James
07/24/20 BMO Capital
Intel price target lowered to $50 from $55 at BMO Capital
07/14/20 Cowen
Nvidia price target raised to $475 from $410 at Cowen
OSTK Overstock.com
$94.11 /

+ (+0.00%)

07/31/20 DA Davidson
Overstock.com price target raised to $103 from $66 at DA Davidson
07/02/20 DA Davidson
Overstock.com price target raised to $66 from $33 at DA Davidson
05/12/20 Jefferies
Overstock.com 130% sales jump positive for Wayfair, says Jefferies
05/06/20 DA Davidson
Wayfair price target raised to $100 from $45 at DA Davidson
IDEX Ideanomics
$1.65 /

+ (+0.00%)

RIOT Riot Blockchain
$4.22 /

+ (+0.00%)

TEUM Pareteum
$0.79 /

+ (+0.00%)

10/22/19 Lake Street
Pareteum downgraded to Hold from Buy at Lake Street
10/22/19 Northland
Northland cuts Pareteum to Market Perform after 'unusually large' restatement
10/22/19 Oppenheimer
Pareteum downgraded to Perform at Oppenheimer
10/22/19 Oppenheimer
Pareteum downgraded to Perform from Outperform at Oppenheimer
SRAX Srax
$2.85 /

+ (+0.00%)

07/06/20
Fly Intel: Top five analyst initiations
07/06/20 B. Riley FBR
B. Riley FBR starts Srax at Buy on 'rapid adoption' of Sequire
07/06/20 B. Riley FBR
Srax initiated with a Buy at B. Riley FBR
TWTR Twitter
$37.69 /

+ (+0.00%)

OSTK Overstock.com
$94.11 /

+ (+0.00%)

NVDA Nvidia
$453.42 /

+ (+0.00%)

GS Goldman Sachs
$204.29 /

+ (+0.00%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

AMD AMD
$86.70 /

+ (+0.00%)

TWTR Twitter
$37.69 /

+ (+0.00%)

NVDA Nvidia
$453.42 /

+ (+0.00%)

IDEX Ideanomics
$1.65 /

+ (+0.00%)

GS Goldman Sachs
$204.29 /

+ (+0.00%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

AMD AMD
$86.70 /

+ (+0.00%)

TWTR Twitter
$37.69 /

+ (+0.00%)

OSTK Overstock.com
$94.11 /

+ (+0.00%)

NVDA Nvidia
$453.42 /

+ (+0.00%)

GS Goldman Sachs
$204.29 /

+ (+0.00%)

BTC Bitcoin
$0.00 /

+ (+0.00%)

BITCOIN Bitcoin
$0.00 /

+ (+0.00%)

AMD AMD
$86.70 /

+ (+0.00%)

TWTR Twitter
$37.69 /

+ (+0.00%)

TEUM Pareteum
$0.79 /

+ (+0.00%)

RIOT Riot Blockchain
$4.22 /

+ (+0.00%)

OSTK Overstock.com
$94.11 /

+ (+0.00%)

NVDA Nvidia
$453.42 /

+ (+0.00%)

IDEX Ideanomics
$1.65 /

+ (+0.00%)

GS Goldman Sachs
$204.29 /

+ (+0.00%)

AMD AMD
$86.70 /

+ (+0.00%)

Thursday
Periodicals
Trump to order government to buy certain drugs from U.S., USA Today says » 10:12
08/06/20
08/06
10:12
08/06/20
10:12
JNJ

Johnson & Johnson

$148.29 /

-0.1 (-0.07%)

, LLY

Eli Lilly

$154.75 /

+0.36 (+0.23%)

, MRK

Merck

$81.48 /

-0.13 (-0.16%)

, PFE

Pfizer

$38.73 /

+0.28 (+0.73%)

, SNY

Sanofi

$51.41 /

-0.27 (-0.52%)

, AZN

AstraZeneca

$56.22 /

+0.3 (+0.54%)

, GSK

GlaxoSmithKline

$41.04 /

-0.17 (-0.41%)

, NVS

Novartis

$83.51 /

+0.07 (+0.08%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.67 /

+1.98 (+3.32%)

President Donald Trump…

President Donald Trump will sign an executive order mandating the federal government to buy certain drugs from U.S. manufacturers rather than foreign companies, USA Today's Michael Collins reports, citing officials. The order, which will be signed at Whirlpool's (WHR) manufacturing facility in Ohio, requires the government to develop a list of "essential" medicines and purchase them as well as other medical supplies from the U.S. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
MRK Merck
$81.48 /

-0.13 (-0.16%)

08/04/20 Piper Sandler
Merck deal sparks interest in GLP-1:glucagon agonists, says Piper Sandler
08/03/20
Fly Intel: Top five analyst upgrades
08/03/20 Goldman Sachs
Merck upgraded to Buy from Neutral at Goldman Sachs
PFE Pfizer
$38.73 /

+0.28 (+0.73%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
NVS Novartis
$83.51 /

+0.07 (+0.08%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

08/06/20 Citi
Investors can refocus on Bristol-Myers story after Eliquis win, says Citi
07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

RHHBY Roche
$0.00 /

+ (+0.00%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

SNY Sanofi
$51.41 /

-0.27 (-0.52%)

PFE Pfizer
$38.73 /

+0.28 (+0.73%)

NVS Novartis
$83.51 /

+0.07 (+0.08%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$154.75 /

+0.36 (+0.23%)

JNJ Johnson & Johnson
$148.29 /

-0.1 (-0.07%)

GSK GlaxoSmithKline
$41.04 /

-0.17 (-0.41%)

BMY Bristol-Myers
$61.67 /

+1.98 (+3.32%)

AZN AstraZeneca
$56.22 /

+0.3 (+0.54%)

Hot Stocks
AstraZeneca enters clinical trial collaboration with Daiichi Sankyo » 08:25
08/06/20
08/06
08:25
08/06/20
08:25
AZN

AstraZeneca

$55.92 /

-0.145 (-0.26%)

Daiichi Sankyo announced…

Daiichi Sankyo announced that it has entered into a clinical trial collaboration with AstraZeneca to evaluate the combination of patritumab deruxtecan, a HER3 directed DXd antibody drug conjugate, or ADC, and Tagrisso, an epidermal growth factor receptor, or EGFR, tyrosine kinase inhibitor, in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer.

ShowHide Related Items >><<
AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

Conference/Events
Susquehanna to hold a virtual conference » 08:01
08/06/20
08/06
08:01
08/06/20
08:01
AXP

American Express

$95.43 /

+2.26 (+2.43%)

, EVTC

Evertec

$31.78 /

-0.42 (-1.30%)

, FIS

FIS

$146.43 /

-0.77 (-0.52%)

, FISV

Fiserv

$98.12 /

-1.465 (-1.47%)

, MA

MasterCard

$328.00 /

+13.68 (+4.35%)

, PAGS

PagSeguro Digital

$39.55 /

+0.58 (+1.49%)

, PYPL

PayPal

$202.94 /

+5.56 (+2.82%)

, TREE

LendingTree

$334.87 /

-1.97 (-0.58%)

, V

Visa

$196.14 /

+3.86 (+2.01%)

, WMT

Walmart

$129.81 /

-1.815 (-1.38%)

, WU

Western Union

$22.89 /

-1.32 (-5.45%)

2020 Get Carded: A…

2020 Get Carded: A Payments Virtual Conference will be held on August 6.

ShowHide Related Items >><<
WU Western Union
$22.89 /

-1.32 (-5.45%)

WMT Walmart
$129.81 /

-1.815 (-1.38%)

V Visa
$196.14 /

+3.86 (+2.01%)

TREE LendingTree
$334.87 /

-1.97 (-0.58%)

PYPL PayPal
$202.94 /

+5.56 (+2.82%)

PAGS PagSeguro Digital
$39.55 /

+0.58 (+1.49%)

MA MasterCard
$328.00 /

+13.68 (+4.35%)

FISV Fiserv
$98.12 /

-1.465 (-1.47%)

FIS FIS
$146.43 /

-0.77 (-0.52%)

EVTC Evertec
$31.78 /

-0.42 (-1.30%)

AXP American Express
$95.43 /

+2.26 (+2.43%)

AXP American Express
$95.43 /

+2.26 (+2.43%)

07/31/20 Wolfe Research
American Express initiated with an Outperform at Wolfe Research
07/27/20 BMO Capital
American Express price target raised to $100 from $96 at BMO Capital
07/15/20
Fly Intel: Top five analyst downgrades
07/15/20 JPMorgan
JPMorgan downgrades AmEx to Underweight on 'spend-driven' model
EVTC Evertec
$31.78 /

-0.42 (-1.30%)

08/05/20 Susquehanna
Evertec price target raised to $38 from $33 at Susquehanna
07/14/20 Goldman Sachs
Evertec initiated with a Neutral at Goldman Sachs
FIS FIS
$146.43 /

-0.77 (-0.52%)

08/05/20 Credit Suisse
FIS price target raised to $160 from $150 at Credit Suisse
08/05/20 Wells Fargo
FIS price target raised to $165 from $150 at Wells Fargo
08/05/20 Stephens
FIS price target raised to $174 from $164 at Stephens
08/03/20 KeyBanc
FIS price target raised to $165 from $140 at KeyBanc
FISV Fiserv
$98.12 /

-1.465 (-1.47%)

07/22/20 Barclays
Fiserv shares undervalued after 'clearing event,' says Barclays
07/14/20 Barclays
Fiserv pullback brings 'unique buying opportunity,' says Barclays
07/14/20 Goldman Sachs
Fiserv initiated with a Conviction Buy at Goldman Sachs
06/29/20 Oppenheimer
Fiserv downgraded to Perform at Oppenheimer
MA MasterCard
$328.00 /

+13.68 (+4.35%)

08/03/20 KeyBanc
MasterCard price target raised to $340 from $300 at KeyBanc
07/31/20 Compass Point
MasterCard price target raised to $370 from $330 at Compass Point
07/20/20 Goldman Sachs
PayPal price target raised to $205 from $170 at Goldman Sachs
07/14/20 Goldman Sachs
MasterCard initiated with a Conviction Buy at Goldman Sachs
PAGS PagSeguro Digital
$39.55 /

+0.58 (+1.49%)

07/27/20 Goldman Sachs
PagSeguro Digital price target raised to $47 from $29 at Goldman Sachs
07/16/20 Deutsche Bank
PagSeguro Digital price target raised to $46 from $40 at Deutsche Bank
06/11/20 Guggenheim
PagSeguro Digital price target raised to $42 from $37 at Guggenheim
05/27/20 KeyBanc
PagSeguro Digital price target raised to $32 from $20 at KeyBanc
PYPL PayPal
$202.94 /

+5.56 (+2.82%)

08/04/20 Stephens
PayPal price target raised to $228 from $194 at Stephens
08/03/20 Barclays
PayPal price target raised to $228 from $210 at Barclays
07/31/20 Keefe Bruyette
PayPal price target raised to $220 from $205 at Keefe Bruyette
07/30/20 Wedbush
PayPal price target raised to $220 from $200 at Wedbush
TREE LendingTree
$334.87 /

-1.97 (-0.58%)

08/05/20 Oppenheimer
LendingTree price target raised to $395 from $275 at Oppenheimer
07/17/20 Northland
LendingTree price target raised to $340 from $250 at Northland
07/17/20 Truist
LendingTree price target raised to $335 from $265 at SunTrust
07/17/20 Needham
LendingTree price target raised to $375 from $275 at Needham
V Visa
$196.14 /

+3.86 (+2.01%)

08/03/20 KeyBanc
Visa price target raised to $215 from $190 at KeyBanc
07/14/20 Goldman Sachs
Visa initiated with a Buy at Goldman Sachs
07/13/20 Wells Fargo
Visa price target raised to $220 from $205 at Wells Fargo
WMT Walmart
$129.81 /

-1.815 (-1.38%)

07/30/20
Fly Intel: Top five analyst initiations
07/30/20 MKM Partners
BJ's Wholesale initiated with a Sell at MKM Partners
07/30/20 MKM Partners
Target initiated with a Sell at MKM Partners
07/30/20 MKM Partners
Costco initiated with a Neutral at MKM Partners
WU Western Union
$22.89 /

-1.32 (-5.45%)

07/30/20 Wolfe Research
Western Union upgraded to Peer Perform from Underperform at Wolfe Research
07/14/20 Goldman Sachs
Western Union initiated with a Sell at Goldman Sachs
07/01/20 Northland
Western Union upgraded to Outperform from Market Perform at Northland
06/10/20
Fly Intel: Top five analyst downgrades
WU Western Union
$22.89 /

-1.32 (-5.45%)

WMT Walmart
$129.81 /

-1.815 (-1.38%)

V Visa
$196.14 /

+3.86 (+2.01%)

TREE LendingTree
$334.87 /

-1.97 (-0.58%)

PYPL PayPal
$202.94 /

+5.56 (+2.82%)

MA MasterCard
$328.00 /

+13.68 (+4.35%)

FISV Fiserv
$98.12 /

-1.465 (-1.47%)

FIS FIS
$146.43 /

-0.77 (-0.52%)

EVTC Evertec
$31.78 /

-0.42 (-1.30%)

AXP American Express
$95.43 /

+2.26 (+2.43%)

  • 17
    Oct
WU Western Union
$22.89 /

-1.32 (-5.45%)

WMT Walmart
$129.81 /

-1.815 (-1.38%)

V Visa
$196.14 /

+3.86 (+2.01%)

PYPL PayPal
$202.94 /

+5.56 (+2.82%)

MA MasterCard
$328.00 /

+13.68 (+4.35%)

AXP American Express
$95.43 /

+2.26 (+2.43%)

WU Western Union
$22.89 /

-1.32 (-5.45%)

WMT Walmart
$129.81 /

-1.815 (-1.38%)

V Visa
$196.14 /

+3.86 (+2.01%)

TREE LendingTree
$334.87 /

-1.97 (-0.58%)

PYPL PayPal
$202.94 /

+5.56 (+2.82%)

MA MasterCard
$328.00 /

+13.68 (+4.35%)

FISV Fiserv
$98.12 /

-1.465 (-1.47%)

FIS FIS
$146.43 /

-0.77 (-0.52%)

EVTC Evertec
$31.78 /

-0.42 (-1.30%)

AXP American Express
$95.43 /

+2.26 (+2.43%)

WU Western Union
$22.89 /

-1.32 (-5.45%)

WMT Walmart
$129.81 /

-1.815 (-1.38%)

V Visa
$196.14 /

+3.86 (+2.01%)

PYPL PayPal
$202.94 /

+5.56 (+2.82%)

PAGS PagSeguro Digital
$39.55 /

+0.58 (+1.49%)

MA MasterCard
$328.00 /

+13.68 (+4.35%)

FISV Fiserv
$98.12 /

-1.465 (-1.47%)

FIS FIS
$146.43 /

-0.77 (-0.52%)

AXP American Express
$95.43 /

+2.26 (+2.43%)

Recommendations
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays » 06:59
08/06/20
08/06
06:59
08/06/20
06:59
MRNA

Moderna

$75.76 /

-2.72 (-3.47%)

, NVAX

Novavax

$173.38 /

+16.23 (+10.33%)

Barclays analyst Gena…

Barclays analyst Gena Wang raised the firm's price target on Moderna (MRNA) to $84 from $68 and keeps an Overweight rating on the shares. The stock closed Wednesday down $2.66 to $75.50. The company's Q2 update highlighted pipeline progress including mRNA-1273 Phase 3 trial enrollment for COVID-19 completion by the end of September, Wang tells investors in a research note. Approximately $400M customer deposits were received as of July 31 for commercial supply of mRNA-1273, and discussions with countries are ongoing, the analyst points out. While Novavax's (NVAX) vaccine data were encouraging, the high neutralizing titers in the mRNA-1273 Phase 1 trial continue to support mRNA-1273's "best-in-class potential," Wang contends.

ShowHide Related Items >><<
NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
NVAX Novavax
$173.38 /

+16.23 (+10.33%)

08/06/20 H.C. Wainwright
Novavax price target raised to $290 from $132 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst downgrades
08/05/20
Fly Intel: Top five analyst upgrades
08/05/20 B. Riley FBR
Novavax price target raised to $257 from $184 at B. Riley FBR
NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

  • 19
    May
  • 12
    Feb
NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

Periodicals
Early Covid vaccine supplies likely to fall short of what is needed, WSJ reports » 06:18
08/06/20
08/06
06:18
08/06/20
06:18
MRNA

Moderna

$75.76 /

-2.72 (-3.47%)

, PFE

Pfizer

$38.45 /

+0.07 (+0.18%)

, NVAX

Novavax

$173.38 /

+16.23 (+10.33%)

, AZN

AstraZeneca

$55.92 /

-0.145 (-0.26%)

Initial supplies of any…

Initial supplies of any successful coronavirus vaccines are now expected to fall short of what is needed, The Wall Street Journal's Peter Loftus reports. Public-health officials estimate more than 100 million Americans, including doctors and nurses, other essential workers and nursing-home residents, should get vaccinated before the general public, but there may only be 10 million to 20 million doses available at first, according to a slide presentation prepared by the U.S. Centers for Disease Control and Prevention staff and shown to a committee of outside vaccine advisers last week. Companies including Moderna (MRNA), AstraZeneca (AZN), Pfizer (PFE) and Novavax (NVAX) have started large clinical trials of their vaccine candidates. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$38.45 /

+0.07 (+0.18%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
PFE Pfizer
$38.45 /

+0.07 (+0.18%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
NVAX Novavax
$173.38 /

+16.23 (+10.33%)

08/05/20
Fly Intel: Top five analyst downgrades
08/05/20
Fly Intel: Top five analyst upgrades
08/05/20 B. Riley FBR
Novavax price target raised to $257 from $184 at B. Riley FBR
08/05/20 Cantor Fitzgerald
Novavax price target raised to $211 from $148 at Cantor Fitzgerald
AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
PFE Pfizer
$38.45 /

+0.07 (+0.18%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

  • 19
    May
  • 12
    Feb
PFE Pfizer
$38.45 /

+0.07 (+0.18%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

PFE Pfizer
$38.45 /

+0.07 (+0.18%)

NVAX Novavax
$173.38 /

+16.23 (+10.33%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

AZN AstraZeneca
$55.92 /

-0.145 (-0.26%)

Earnings
Ball Corp. expects to grow EPS 'this year' » 06:15
08/06/20
08/06
06:15
08/06/20
06:15
BLL

Ball Corp.

$75.09 /

-0.03 (-0.04%)

"Our company…

"Our company continues to operate from a position of strength. Ample liquidity and cash flow continue to bolster our ability to accelerate growth investments while continuing to return value to shareholders. Given the exciting growth trajectory in our North American beverage business, we foresee 2020 capital expenditures exceeding $900 million and additional EVA-enhancing opportunities in 2021 and beyond," said Scott Morrison, senior vice president and CFO. "We are proud of our colleagues around the world. During the quarter, we faced many challenges on both a human and operational level, and our team came together to execute our global business strategy as effectively and safely as possible. While lingering challenges are likely, our products and operations have proven their resiliency by exiting the second quarter with notable momentum across all of our operations. We currently expect to grow our earnings per diluted share this year while returning capital to our shareholders. Beyond 2020, we look forward to continuing to grow our EVA dollars on an even larger capital base and achieving our long-term diluted earnings per share growth goal of 10 to 15 percent," CEO John Hayes said.

ShowHide Related Items >><<
BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

07/15/20 Jefferies
Canpack's new Scranton plant 'modest negative' for Ball, Crown, says Jefferies
07/15/20 Citi
Can-Pack entry to U.S. would be negative for Ball, Crown, says Citi
07/13/20 Jefferies
Ball Corp. assumed with a Hold at Jefferies
06/01/20 Atlantic Equities
Ball Corp. initiated with a Neutral at Atlantic Equities
BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

Earnings
Ball Corp. reports Q2 EPS 65c, consensus 56c » 06:12
08/06/20
08/06
06:12
08/06/20
06:12
BLL

Ball Corp.

$75.09 /

-0.03 (-0.04%)

Reports Q2 revenue $2.8B,…

Reports Q2 revenue $2.8B, consensus $2.86B. "The resiliency of our businesses and ability to maintain safe, continuous business operations is reflected in our results. Our team is working diligently to satisfy the needs of our global aluminum packaging and aerospace customers amidst a dynamic operating environment. Ball's financial strength, growth investments, sustainable products and ability to provide for our employees, customers and communities where we operate has never been more important," said John Hayes, chairman, president and CEO. "During the quarter, our company posted 2 percent comparable earnings per diluted share growth on flat operating earnings with strong aluminum beverage can demand in North America continuing to outpace regional supply offset somewhat by high single-digit volume declines in EMEA, early-quarter sharp volume declines in South America aluminum beverage and an aerospace supply chain issue impacting segment results. Our global beverage, aerosol and aerospace businesses rebounded swiftly following the initial impact of the global pandemic and all are exiting the quarter with momentum for improved performance in the second half and beyond. With demand for our aluminum packaging solutions and aerospace technologies increasing even higher than we anticipated, much needed capacity additions and hiring will benefit our company and customers in the second half of 2020 and beyond. Our previously announced projects are on track and we will continue to deploy additional capital across our existing business portfolio to support new customer contracts. Ball remains well positioned to grow diluted earnings per share, and deliver shareholder returns now and into the future," Hayes said.

ShowHide Related Items >><<
BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

07/15/20 Jefferies
Canpack's new Scranton plant 'modest negative' for Ball, Crown, says Jefferies
07/15/20 Citi
Can-Pack entry to U.S. would be negative for Ball, Crown, says Citi
07/13/20 Jefferies
Ball Corp. assumed with a Hold at Jefferies
06/01/20 Atlantic Equities
Ball Corp. initiated with a Neutral at Atlantic Equities
BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

BLL Ball Corp.
$75.09 /

-0.03 (-0.04%)

Recommendations
Now is the time to buy Goldman Sachs, says Piper Sandler » 06:11
08/06/20
08/06
06:11
08/06/20
06:11
GS

Goldman Sachs

$204.58 /

+2.93 (+1.45%)

Piper Sandler analyst…

Piper Sandler analyst Jeffery Harte believes now is the time to buy shares of Goldman Sachs. Answers to many investor concerns have become increasingly evident in recent weeks, and the capital markets operating environment continues to be a "pleasant surprise," Harte tells investors in a research note. The 1MDB settlement with Malaysia removes a "major litigation overhang" and Goldman's "exceptional" Q2 trading results show it still has the capacity to capitalize on market volatility spikes, says the analyst. Harte keeps an Overweight rating on the shares with a $245 price target.

ShowHide Related Items >><<
GS Goldman Sachs
$204.58 /

+2.93 (+1.45%)

GS Goldman Sachs
$204.58 /

+2.93 (+1.45%)

07/20/20 Berenberg
Goldman Sachs price target raised to $200 from $160 at Berenberg
07/16/20 DA Davidson
Goldman Sachs price target raised to $238 from $215 at DA Davidson
07/16/20 Oppenheimer
Goldman Sachs price target raised to $355 from $335 at Oppenheimer
07/16/20 RBC Capital
Goldman Sachs price target raised to $225 from $200 at RBC Capital
GS Goldman Sachs
$204.58 /

+2.93 (+1.45%)

GS Goldman Sachs
$204.58 /

+2.93 (+1.45%)

GS Goldman Sachs
$204.58 /

+2.93 (+1.45%)

GS Goldman Sachs
$204.58 /

+2.93 (+1.45%)

Conference/Events
Moderna participates in a conference call with Oppenheimer » 04:55
08/06/20
08/06
04:55
08/06/20
04:55
MRNA

Moderna

$75.76 /

-2.72 (-3.47%)

Conference call with…

Conference call with management will be held on August 6 hosted by Oppenheimer.

ShowHide Related Items >><<
MRNA Moderna
$75.76 /

-2.72 (-3.47%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
MRNA Moderna
$75.76 /

-2.72 (-3.47%)

  • 19
    May
  • 12
    Feb
MRNA Moderna
$75.76 /

-2.72 (-3.47%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

MRNA Moderna
$75.76 /

-2.72 (-3.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.